Separately, Zacks Investment Research cut shares of Kazia Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd.
NASDAQ KZIA traded up $0.07 during trading hours on Monday, reaching $3.22. The company’s stock had a trading volume of 329 shares, compared to its average volume of 4,852. The stock has a market cap of $20.72 million, a PE ratio of -3.32 and a beta of 1.63. Kazia Therapeutics has a fifty-two week low of $2.04 and a fifty-two week high of $4.27. The company’s 50-day moving average is $3.15 and its two-hundred day moving average is $2.92.
About Kazia Therapeutics
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.